Genable Technologies Ltd., Dublin, Ireland, has recently expanded its intellectual property portfolio having obtained grants for two additional US patent applications on its novel suppression and replacement technology. The first of Genable’s recently granted US patents encompasses aspects of RNA interference (RNAi) mediated suppression and replacement (12/710343), while the second US patent (13/539,835) is focused on the generation of optimized replacement vectors for incorporation in innovative therapeutic strategies such as suppression and replacement therapies.
Avril Daly, CEO of Ireland’s Fighting Blindness commented “As a patient-led research charity the development of appropriate therapies for unmet medical needs is paramount therefore our organization was a founding investor in Genable Technologies. Having these newly granted patents improves the likelihood that the products will become viable therapies for patients with genetic blindness and we congratulate the inventors and the Company.”
Dr Stephen Rose, Chief Research Officer at US charity Foundation Fighting Blindness added “our key focus is to enable effective therapies get to patients and we recognize that securing IPR is a very important step on this journey. As such, we continue to support Genable as they bring their lead therapy GT038 to the clinic”.
Suppression and replacement technology represents a unique solution that enables treatment of dominantly inherited genetic disorders. The Company’s lead product, GT038, is focused on an ocular indication, Rhodopsin-linked autosomal dominant Retinitis Pigmentosa. GT038 has been granted orphan drug status and is currently in late preclinical development.
About Genable Technologies Ltd
Genable Technologies Ltd. is a privately held, venture capital backed Dublin (Ireland) based bio-pharmaceutical company and secured financing from Fountain Healthcare Partners and Delta Partners in 2011. The company is developing new gene therapies to treat "dominant" genetic diseases based on the pioneering work of Professor Jane Farrar, Dr Paul Kenna & Professor Peter Humphries of Trinity College Dublin. The background research has been supported by Fighting Blindness Ireland, Science Foundation Ireland, Foundation Fighting Blindness-National Neurovision Research Institute (USA), Enterprise Ireland & EVI-GenoRet (EU FP6-funded). www.genable.net
About Fighting Blindness
Irish research funded by Fighting Blindness has made a global impact in the search for therapies and cures for conditions causing sight loss. Since 1983, the patients who founded the organisation met regularly to help each other cope with the reality of degenerating vision. There was no treatment, nor was there real hope of one. Now not only do we understand how the conditions develop, but we also know what the treatments will look like. Since its founding, Fighting Blindness has invested over €10 million in Irish research, and our goal of cures and treatments is in sight. Our research is also contributing to international discoveries and developments and many clinical trials are being undertaken in both genetically inherited and age related conditions.
About Foundation Fighting Blindness
Foundation Fighting Blindness is a US-based non-profit organization driving the research that will lead to preventions, treatments and cures for retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases that affects more than 10 million Americans. Since 1971, the Foundation has raised more than $550 million as the leading non-governmental funder of inherited retinal research. Breakthrough Foundation-funded studies using gene therapy have restored significant vision in children and young adults who were previously blind, paving the way for additional clinical trials to treat a variety of retinal degenerative diseases. With a coveted four-star rating from Charity Navigator, the Foundation also has nearly 50 chapters that provide support, information and resources to affected individuals and their families in communities across the country. http://www.fightblindness.org/
For more information please contact:
Dr. Jason Loveridge,
CEO Genable Technologies Ltd.
c/o Delta Partners
Media House South County Business Park
Leopardstown Dublin 18 Ireland
Ph. +33 674177812